SPT — Investor Presentation 2021

Mar 24, 2021

1789 TT

ScinoPharm

March 24, 2021

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The information contained in this presentation is ScinoPharm’s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty , express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to , the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks , uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

2

==> picture [82 x 26] intentionally omitted <==

Table of Content

 Business Overview

 Business Update and Outlook

 Financial Performance

3

==> picture [720 x 88] intentionally omitted <==

Business Overview

4

Flexibility to Stabilize Operations and Grow Healthy

 Stable market demand after outbreak of covid-19 pandemic, but adjusted production/shipping schedule to accommodate raw material supply change due to disruption on global logistics

 2020 revenue achieved NTD 3,083 million, up 6.6% yoy, with NPAT NTD 282 million, up 30.2% yoy, and NPAT margin 9.2%

 Adjusted financial assets/liabilities to strengthen capital structure and cash reserve

5

Extend Generic API Core Business to New Markets

• Leverage Tainan/Changshu production advantage with better sales/production coordination to stably supply JP market

• on-

• Changshu site, in Sep. 2020, completed CFDI’s 1[st ] site inspection for Sodium Phenylbutyrate, which is expected to launch by Chinese customer in 2021

• 3 new CFDI on-site inspection is scheduled in 2021, w/w 1 was completed in Feb. 2021

• 5 generic APIs approved in China and Japan to pave the way for both markets

• CDMO business growth

• 1 CDMO product (MAA) approved by EMA

• 2 CDMO products submitted to EMA and FDA by customers

6

Injectables for Long-term Development

 3 drug products (in-house development + outsourcing production) continue generating revenue with multiple drug products development in progress

 1[st] ANDA of in-house peptides prefilled-syringe product submitted to FDA in May, 2020 – Response to FDA review in progress

 Registration batches of Vial Product Line (prefilledsyringed /pen device) and Cartridge Product Line (liquid solution/ lyophilized powder) were completed

• Preparing documentation for submission

• Aim to trigger the 1[st] TFDA on-site inspection

7

Enrich Generic API Portfolio for Future Business Opportunity

 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA

• 869 active DMFs worldwide with 63 US DMFs

8

==> picture [720 x 88] intentionally omitted <==

Business Update and Outlook

9

Business Strategies

==> picture [237 x 220] intentionally omitted <==

----- Start of picture text -----

Advancing to
Injectables
----- End of picture text -----

==> picture [236 x 220] intentionally omitted <==

----- Start of picture text -----

Optimize
Existing Generic
API Portfolio
----- End of picture text -----

==> picture [237 x 220] intentionally omitted <==

----- Start of picture text -----

Expand CDMO
Business
----- End of picture text -----

==> picture [695 x 167] intentionally omitted <==

----- Start of picture text -----

Actively Develop Japan, China and Emerging Markets
----- End of picture text -----

10

==> picture [161 x 151] intentionally omitted <==

----- Start of picture text -----

Optimize
Existing
Generic API
Portfolio
----- End of picture text -----

1. Existing Generic API Portfolio

==> picture [490 x 183] intentionally omitted <==

----- Start of picture text -----

38
40 Data as of 2021/02/28
35 Pipeline
30 Approved
20
25
20
12
15
10 18 7 6 6
5 4 2 3 2 2 2 2 1
5 2 4 3 2 1 1 2 2 1
0
----- End of picture text -----

==> picture [370 x 55] intentionally omitted <==

==> picture [33 x 32] intentionally omitted <==

2. 2020 A roved Generic APIs pp

Product	Region	Indication	Brand Marketer
Capecitabine	CN	Various cancers	Roche
Dantrolene Sodium	CN	Skeletal Muscle Relaxant	Par Sterile Products
Tamsulosin HCl	CN	Benign prostatic hyperplasia	Sanofi Aventis
Galantamine HBr	JP	Alzheimer’s disease	Janssen
Topiramate	JP	Anti-convulsant	Janssen

11

==> picture [161 x 150] intentionally omitted <==

----- Start of picture text -----

Expand
CDMO
Business
----- End of picture text -----

1. CDMO Business

==> picture [528 x 246] intentionally omitted <==

----- Start of picture text -----

Data as of 2021/02/28
14
12
10 7
8 1 SciAnda (Changshu)
6
ScinoPharm Taiwan
6
4 7 7
6
4
2
0
Phase 1 Phase 2 Phase 3 Commercial
----- End of picture text -----

Data as of 2021/02/28

2. 2020 A roved CDMO Product pp

Product	Region	Indication	Brand Marketer
Quofenix	EU	Anti-biotic	Menarini

3. Two CDMO products submitted to EMA and FDA by customers

12

==> picture [161 x 151] intentionally omitted <==

----- Start of picture text -----

Advancing
to
Injectables
----- End of picture text -----

==> picture [127 x 100] intentionally omitted <==

Peptides

==> picture [134 x 114] intentionally omitted <==

Sterile Injectables

==> picture [132 x 114] intentionally omitted <==

Pen Injectors

• Profit-sharing from 3 drug products (in-house development + outsourcing production)

• ANDA of 1[st] in-house prefilled-syringe product was submitted to FDA in May, 2020 – Response to FDA review

• Registration batches of Vial Product Line (prefilled-syringed /pen device) and Cartridge Product Line (liquid solution/ lyophilized powder) products were produced

• Aim to trigger the 1[st] TFDA on-site inspection in Apr. 2021

• Target to submit the 2[nd] in-house produced ANDA and 1[st] NDA (505(b)(2)) in 2021

13

==> picture [666 x 120] intentionally omitted <==

----- Start of picture text -----

Actively Develop Japan, China and Emerging Markets
----- End of picture text -----

Japan Market

• Generic drug market share in Japan is increasing, which is in favor of API suppliers

• 2018：74%  2020：79%

• Become the largest Galantamine HBr generic API supplier in Japan in 2020

• Indication：Alzheimer’s disease

• Japan market size：c. USD 200 million

 Leverage Japan’s late patent expiration and our new injectables capacity to explore opportunities for generic APIs + CDMO projects

14

China Market

• Changshu site, in Sep. 2020, completed CFDI’s 1[st] on-site inspection for Sodium Phenylbutyrate, and will enter China local market after approval

• Customer approval expected in Mar./Apr. and to launch as orphan drug

  • Indication：Urea cycle disorders

• Changshu site, in Feb. 2021, completed CFDI’s on-site inspection for NCE - Donafenib

 Customer approval expected in May, 2021 and to launch afterwards

  - **Indication：Advanced liver cancer first-line treatment**

  - **1[st] year sales projected by research report：c. RMB 220 million**

• Target another 2 on-site inspections in 2021

• Customer’s Fondaparinux Sodium PFS was approved as the 4[th] generic drug supplier and launched in China in Feb. 2021

• Indication：Anti-thrombotic

• Market Size：c. RMB 200 million

15

2021 API Product Approval Plan (I)

==> picture [81 x 27] intentionally omitted <==

Type	Product	Region	Indication	Brand Marketer
Generic API	Fondaparinux Sodium	CN( )	Anti-thrombotic	Mylan
Generic API	Irinotecan HCl	CN	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN	Breast cancer	ANI Pharmaceuticals
Generic API	Sodium Phenylbutyrate	CN	Urea cycle disorders	Horizon Therapeutics
Generic API	Azilsartan	CN	Hypertension	Arbor Pharmaceuticals
Generic API	Letrozole	CN	Breast cancer	Novartis
Generic API	Bimatoprost	CN	Glaucoma	Allergan

==> picture [19 x 18] intentionally omitted <==

Data as of 2021/02/28

：Approved

16

==> picture [81 x 27] intentionally omitted <==

2021 API Product Approval Plan (II)

Type	Product	Region	Indication	Brand Marketer
Generic API	Regadenoaon	US	MPI	Astellas
Generic API	＊Pemetrexed Disodium 7H2O CEP	EU	Non-small cell lung cancer	Eli Lilly
Generic API	Topiramate	EU	Weight management	Vivus
CDMO API	Donafenib	CN	Cancer	Suzhou Zelgen
CDMO API	Leuprolide Mesylate	US/EU	Cancer	Foresee
CDMO API	Eflornithine	US/EU	FAP	CPP

＊： Collaborative project with partner for drug product development

Data as of 2021/02/28

17

==> picture [720 x 88] intentionally omitted <==

Financial Performance

18

Consolidated Income Statement

In NTD Million, except for EPS	2020 (Audited)	2020 (Audited)	YoY	2019 (Audited)	2019 (Audited)
Revenue	3,083	100%	7%	2,893	100%
Gross Profit	1,317	43%	12%	1,176	41%
Operating Profit	376	12%	41%	267	9%
Net Profit before Tax	359	12%	35%	265	9%
Net Profit after Tax	282	9%	30%	217	8%
EPS (NTD)	0.36	-	-	0.27	-

19

2020 Sales Distribution

==> picture [686 x 250] intentionally omitted <==

----- Start of picture text -----

Drug
Product India China Others
7% 11% 3% 9%
CDMO
24%
US+Canada
Generic 19%
Japan
API
19%
69%
EU
39%
by Business CNS Others
by Region
29% 13%
----- End of picture text -----

by Indication

20

Sales Distribution – YoY

B Business Unit: USD y Generic API CDMO Drug Product 2020 Sales 71.8M 25.2M 7.5M YoY 2.1% 78.7% -18.8% B Indication y Oncology CNS Others 2020 Sales 60.5M 30.1M 13.9M YoY -2.3% 54.6% 13.6%

By Region US & EU Japan India China Others Canada 2020 Sales 40.4M 20.4M 19.5M 12.1M 3.1M 9.0M YoY 41.5% 10.9% 4.0% -4.4% -22.8% -20.4%

21

Consolidated Balance Sheet

In NTD Million	2020/12/31 (Audited)	2020/12/31 (Audited)	2019/12/31 (Audited)	2019/12/31 (Audited)
Cash and Cash Equivalents	4,055	34%	3,305	28%
Accounts Receivable	387	3%	590	5%
Inventories	1,246	11%	1,124	10%
Property, Plant & Equipment	4,211	36%	4,434	38%
Other Current/Non-Current Assets	1,948	16%	2,222	19%
Total Assets	11,847	100%	11,675	100%
Financial Debt	9	0%	234	2%
Other Current Liabilities	677	6%	508	4%
Other Non-Current Liabilities	631	5%	673	6%
Total Liabilities	1,317	11%	1,415	12%
Total Shareholders' Equities	10,530	89%	10,260	88%

22

Consolidated Cash Flow Statement

In NTD million	2020 (Audited)	2019 (Audited)
From Operating Activities	946	789
From Investing Activities	242	(98)
From Financing Activities	(445)	(1,572)
Effect of foreign exchange rate changes	7	(17)
Net Change in Cash	750	(898)
Beginning Balance	3,305	4,203
Ending Balance	4,055	3,305

23

==> picture [720 x 88] intentionally omitted <==

Q & A

24

==> picture [81 x 27] intentionally omitted <==

==> picture [676 x 127] intentionally omitted <==

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT

25

Appendix: ScinoPharm at a Glance

• Est. in 1997 in Taiwan (Tainan) with cGMP plants/R&D in Tainan and Changshu and marketing forces in Tainan, Shanghai and Tokyo

• Specializes in high potency (cytotoxic/steroid) API and injectable R&D and manufacturing with customers worldwide

• 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA*

• 869 active DMFs worldwide with 63 US DMFs

• 150+ contract projects with 7 approved/launched (5 NCEs) and 8 in phase 3 for NDA/MAA filing in 1-3 years*

 Certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority

• Data as of 2021/02/28

26